Pipeline Previews

October 2015 | Volume 14 | Issue 10 | Features | 1176 | Copyright © October 2015


Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition, we will inform our readers about the latest drugs receiving Food and Drug Administration (FDA) approval.

Meeting Features Everything New in the World of Plastic Surgery

The American Society of Plastic Surgeons (ASPS) 84th annual scientific conference, Plastic Surgery: The Meeting will be held October 16-20 at the Boston Convention and Exhibition Center in Boston, has been skillfully developed to provide an extraordinary experience to plastic surgeons, residents, and other allied health professionals interested in bringing the most leading- edge clinical information to their practice, and enhancing patient satisfaction and surgical outcomes.

Novartis Launches First U.S. 'Biosimilar' Drug

Novartis kicked off a new era in U.S. medicine with the launch of the first "biosimilar" copy of a biotechnology drug approved in the United States, at a discount of 15 percent to the original. Novartis said the U.S. wholesale list price for a 300 microgram syringe of Zarxio was $275.66, with the 480 mcg version costing $438.98.